高级别浆液性卵巢癌中ETAR mRNA表达的临床意义及ETAR衍生融合多肽对癌症进展的抑制作用研究
该研究纳入徐州市中心医院2007年1月1日至2017年12月31日接受手术且病理确诊为高级别卵巢浆液性癌(HGSOC)的126例患者,检测癌组织ETAR mRNA表达并分析临床意义;同时设计ETAR羧基末端融合多肽,在体外观察其对卵巢癌细胞迁移、侵袭、化疗敏感性及β-arrestin-1表达的影响。结果显示ETAR mRNA高表达与腹水量、铂类耐药及CA125水平显著相关,高表达者5年无进展生存率和总生存率均显著低于低表达者;ETAR-C融合多肽在体外对卵巢癌细胞具有抑制效果。
要点
- HGSOC组织中ETAR mRNA高表达与腹水量、铂类药物耐药及血清CA125水平显著有关(P均<0.05)。
- ETAR mRNA高表达者5年无进展生存率18.4%、总生存率38.2%,低表达者分别为28.0%、52.0%(P=0.046、P=0.034)。
- ETAR-C融合多肽在体外可抑制卵巢癌细胞迁移、侵袭并提高顺铂耐药细胞的抑制率,作者认为其具有临床应用潜力。
核心结论
- ETAR mRNA高表达的HGSOC患者预后显著差于ETAR mRNA低表达者,ETAR可能成为HGSOC治疗的新靶点。
- 干扰ETAR与β-arrestin-1相互作用的ETAR-C融合多肽在体外具有良好的抑制卵巢癌细胞效果,作者认为其具有临床应用潜力。
研究设计与样本
- 回顾性收集2007年1月1日至2017年12月31日在徐州市中心医院接受手术治疗、术后病理确诊为HGSOC且有完整临床病理及随访资料的患者共126例,采用逆转录-PCR检测癌组织ETAR mRNA表达。
- 以ETAR羧基末端氨基酸序列为基础设计ETAR-C融合多肽,体外表达纯化后,用划痕实验和侵袭实验检测其对SKOV3和CAOV3细胞迁移与侵袭能力的影响。
- 用四甲基偶氮唑蓝(MTT)比色法检测ETAR-C融合多肽对顺铂耐药SKOV3/cDDP和CAOV3/cDDP细胞化疗敏感性的影响,用蛋白印迹法检测其对SKOV3和CAOV3细胞中β-arrestin-1表达的影响。
主要发现
- HGSOC组织中ETAR mRNA相对表达水平为18.6±5.1;X-Tile软件分析最佳截断值为61.7%,据此分为高表达组76例和低表达组50例。
- ETAR mRNA高表达与HGSOC患者腹水量、铂类药物耐药和血清CA125水平显著有关(P均<0.05),与年龄及术后残留灶大小无关(P均>0.05)。
- ETAR mRNA高表达组与低表达组的5年无进展生存率分别为18.4%和28.0%,5年总生存率分别为38.2%和52.0%,差异均有统计学意义(P=0.046,P=0.034)。
- 划痕实验和侵袭实验显示,内皮素1(ET-1)与ET-1+ETAR-C分别处理后SKOV3和CAOV3细胞的划痕愈合率和细胞侵袭率比较,差异均有统计学意义(P均<0.05)。
- 加入4、6、8、10、12、24 μg/ml顺铂后,ETAR-C融合多肽处理的SKOV3/cDDP和CAOV3/cDDP细胞抑制率均显著高于对照细胞(P均<0.05)。
关键数值与推荐
- HGSOC组织中ETAR mRNA相对表达水平为18.6±5.1,X-Tile软件分析最佳截断值为61.7%。
- ETAR mRNA高表达组76例,低表达组50例,高表达与腹水量、铂类耐药及CA125水平显著相关(P均<0.05)。
- 高表达组与低表达组5年无进展生存率分别为18.4%和28.0%(P=0.046),5年总生存率分别为38.2%和52.0%(P=0.034)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical significance of endothelin A receptor (ETAR) expression in high-grade serous ovarian carcinoma (HGSOC). To design ETAR carboxyl terminal (ETAR-C) amino acids derived polypeptide and to study the inhibitory effect on ovarian epithelial carcinoma cells in vitro. Methods: (1) A total of 126 patients who received surgical treatment and were diagnosed with HGSOC by postoperative pathological examination in Central Hospital of Xuzhou from January 1, 2007 to December 31, 2017 were selected. All patients had completed clinicopathological data and follow-up data. Cancer tissue samples were collected and ETAR mRNA expression in HGSOC tissues was detected by reverse transcript-PCR. The clinical significance was analyzed. (2) ETAR-C fusion polypeptide was designed based on the sequence of carboxyl terminal amino acids of ETAR, expressed and purified in vitro. The effects of ETAR-C fusion polypeptide on migration and invasion ability of ovarian cancer SKOV3 and CAOV3 cells were detected by scratch test and invasion test, respectively. The effect of ETAR-C fusion polypeptide on chemosensitivity of cisplatin-resistant ovarian cancer SKOV3/cDDP and CAOV3/cDDP cells was determined by methyl thiazolyl tetrazolium (MTT) colorimetric assay. The effect of ETAR-C fusion polypeptide on β-arrestin-1 expression in ovarian cancer SKOV3 and CAOV3 cells was detected by western blot. Results: (1) The relative expression level of ETAR mRNA in HGSOC tissues was 18.6±5.1. Patients with HGSOC were divided into high ETAR mRNA expression (n=76) and low ETAR mRNA expression (n=50) with 61.7% as cut-off value analyzed by X-Tile software. High expression of ETAR mRNA was significantly correlated with abdominal water volume, platinum drug resistance, and cancer antigen 125 (CA125) value in HGSOC patients (all P<0.05), but was not related to the age of patients with HGSOC and the size of postoperative residual lesions (all P>0.05). The 5-year progression free survival rates were 18.4% and 28.0%, and the 5-year overall survival rates were 38.2% and 52.0% in HGSOC patients with high and low ETAR mRNA expression respectively, there were statistically significant differences (P=0.046, P=0.034). (2) The results of scratch test and invasion test showed that the scratch healing rate and cell invasion rate of SKOV3 or CAOV3 cells treated with endothelin-1 (ET-1) and ET-1+ETAR-C were respectively compared, and the differences were statistically significant (all P<0.05). MTT assay showed that the inhibition rates of ETAR-C fusion polypeptide treated in SKOV3/cDDP and CAOV3/cDDP cells were significantly higher than those of control cells after the addition of 4, 6, 8, 10, 12, and 24 μg/ml cisplatin (all P<0.05). Western blot analysis showed that the relative expression levels of β-arrestin-1 in SKOV3 or CAOV3 cells treated with ET-1 and ET-1+ETAR-C were 1.85±0.09 and 1.13±0.09 (SKOV3 cells), 2.14±0.15 and 1.66±0.12 (CAOV3 cells), respectively. The differences were statistically significant (all P<0.05). Conclusions: The prognosis of HGSOC patients with high expression of ETAR mRNA is significantly worse than those with low expression of ETAR mRNA. ETAR might be a new target for HGSOC treatment. The ETAR-C fusion polypeptide that interferes with the interaction of ETAR and β-arrestin-1 has good inhibitory effect on ovarian cancer cells in vitro, and might have clinical application potential. 目的: 探讨高级别卵巢浆液性癌(HGSOC)组织中内皮素A受体(ETAR)表达的临床意义;设计ETAR羧基末端(ETAR-C)氨基酸序列来源的ETAR-C融合多肽,研究其对卵巢上皮性癌(卵巢癌)细胞的体外抑癌作用。 方法: (1)选择2007年1月1日至2017年12月31日在徐州市中心医院接受手术治疗、术后病理检查确诊为HGSOC且有完整临床病理资料及随访资料的患者共126例,收集其癌组织标本,采用逆转录-PCR技术检测HGSOC组织中ETAR mRNA的表达,并分析其临床意义。(2)以ETAR-C氨基酸序列为基础设计ETAR-C融合多肽,通过体外表达、纯化ETAR-C融合多肽,采用划痕实验、侵袭实验分别检测ETAR-C融合多肽处理后卵巢癌SKOV3和CAOV3细胞的迁移、侵袭能力,四甲基偶氮唑蓝(MTT)比色法检测ETAR-C融合多肽处理后顺铂耐药卵巢癌SKOV3/cDDP和CAOV3/cDDP细胞的化疗敏感性,蛋白印迹(western blot)法检测ETAR-C融合多肽处理后卵巢癌SKOV3和CAOV3细胞中β抑制蛋白1(β-arrestin-1)的表达。 结果: (1)HGSOC组织中ETAR mRNA的相对表达水平为18.6±5.1,X-Tile软件分析显示最佳截断值为61.7%,据此将HGSOC患者分为ETAR mRNA高表达(76例)和低表达(50例)。ETAR mRNA高表达与HGSOC患者的腹水量、铂类药物耐药和血清癌抗原125(CA125)水平均显著有关(P均<0.05),而与HGSOC患者的年龄、术后残留灶大小无关(P均>0.05);ETAR mRNA高表达和低表达患者的5年无进展生存率分别为18.4%、28.0%,5年总生存率分别为38.2%、52.0%,两者分别比较,差异均有统计学意义(P=0.046,P=0.034)。(2)划痕实验和侵袭实验结果均显示,内皮素1(ET-1)、ET-1+ETAR-C分别处理后SKOV3和CAOV3细胞的划痕愈合率和细胞侵袭率分别比较,差异均有统计学意义(P均<0.05)。MTT比色法检测显示,加入不同浓度(4、6、8、10、12、24 μg/ml)顺铂后,ETAR-C融合多肽处理后的SKOV3/cDDP和CAOV3/cDDP细胞的抑制率均显著高于对照细胞(P均<0.05)。western blot法检测显示,ET-1、ET-1+ETAR-C分别处理后SKOV3细胞(分别为1.85±0.09、1.13±0.09)和CAOV3细胞(2.14±0.15、1.66±0.12)中β-arrestin-1蛋白的表达水平分别比较,差异均有统计学意义(P均<0.05)。 结论: ETAR mRNA高表达HGSOC患者的预后显著差于ETAR mRNA低表达者,ETAR可能成为HGSOC治疗的新靶点。干扰ETAR与β-arrestin-1相互作用的ETAR-C融合多肽具有良好的体外抑制卵巢癌细胞的效果,具有临床应用潜力。.
引用
- Zhang YL, Xia XK, Zhang M, et al. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression]. Zhonghua Fu Chan Ke Za Zhi. 2023. PMID: 38123199. doi:10.3760/cma.j.cn112141-20230801-00029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。